Hochman Cole Investment Advisors Inc. Has $440,000 Stake in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Hochman Cole Investment Advisors Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 24.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,165 shares of the biopharmaceutical company’s stock after selling 3,257 shares during the period. Hochman Cole Investment Advisors Inc.’s holdings in Pfizer were worth $440,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of PFE. Fisher Asset Management LLC raised its holdings in Pfizer by 3.7% during the second quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after acquiring an additional 1,559,405 shares in the last quarter. California Public Employees Retirement System raised its holdings in Pfizer by 14.0% during the fourth quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after acquiring an additional 2,504,336 shares in the last quarter. Sanders Capital LLC raised its holdings in Pfizer by 3.3% during the second quarter. Sanders Capital LLC now owns 18,749,080 shares of the biopharmaceutical company’s stock worth $910,953,000 after acquiring an additional 606,700 shares in the last quarter. APG Asset Management N.V. raised its holdings in Pfizer by 1.4% during the fourth quarter. APG Asset Management N.V. now owns 16,360,380 shares of the biopharmaceutical company’s stock worth $624,704,000 after acquiring an additional 228,300 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Pfizer by 1.2% during the fourth quarter. Rhumbline Advisers now owns 9,449,884 shares of the biopharmaceutical company’s stock worth $412,487,000 after acquiring an additional 113,506 shares in the last quarter. 71.58% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on PFE. Morgan Stanley downgraded Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $48.00 to $40.00 in a research report on Tuesday, July 30th. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Monday, July 29th. Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Finally, UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Fourteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $46.67.

In other news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at $3,524,136. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Shares of Pfizer stock traded down $0.74 on Friday, hitting $34.34. The stock had a trading volume of 20,323,181 shares, compared to its average volume of 35,302,192. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The business’s 50 day moving average is $39.60 and its two-hundred day moving average is $41.43. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The stock has a market cap of $194.03 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.80 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 4.19%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s payout ratio is 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is the strike price in options trading?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
Line Corp  Shares Sold by CSat Investment Advisory L.P.
Line Corp Shares Sold by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report